Follicular Lymphoma Therapy Shows Cost-Time Trade-Offs
Liso-cel outperformed mosunetuzumab in progression-free survival, healthcare resource usage, and quality of life but came with a much higher overall cost, a modeling study found.
Medscape Medical News
source https://www.medscape.com/viewarticle/follicular-lymphoma-therapy-shows-cost-time-trade-offs-2024a1000opd?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/follicular-lymphoma-therapy-shows-cost-time-trade-offs-2024a1000opd?src=rss
Comments
Post a Comment